COCRYSTAL PHARMA, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
COCRYSTAL PHARMA, INC. (COCP) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$167.61 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2014-03-31
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2013-12-31 was -$1.01M, a 599.15% decline year-over-year.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2013-09-30 was $325.22K.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2013-06-30 was $392.65K, a 737.80% increase year-over-year.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2013-03-31 was $129.21K.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2013 was -$167.61K.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2012 was -$80.69K, a 107.70% decline from fiscal 2011.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2011 was $1.05M.
- COCRYSTAL PHARMA, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2010 was -$49.37K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2013-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | -$689.47K derived: sum of 2 quarters · filed 2014-03-31 | -$296.82K derived: sum of 3 quarters · filed 2014-03-31 | -$167.61K 10-K · filed 2014-03-31 | ||
| 2013-09-30 | $325.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-18 | $717.87K derived: sum of 2 quarters · filed 2013-11-18 | $847.08K 10-Q · filed 2013-11-18 | $1.05M derived: sum of 4 quarters · filed 2014-03-31 | ||
| 2013-06-30 | $392.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-15 | $521.86K 10-Q · filed 2013-08-15 | $725.14K derived: sum of 3 quarters · filed 2014-03-31 | $624.46K derived: sum of 4 quarters · filed 2014-03-31 | ||
| 2013-03-31 | $129.21K 10-Q · filed 2013-05-10 | $332.49K derived: sum of 2 quarters · filed 2014-03-31 | $231.81K derived: sum of 3 quarters · filed 2014-03-31 | $278.67K derived: sum of 4 quarters · filed 2014-03-31 | ||
| 2012-12-31 | $203.28K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $102.60K derived: sum of 2 quarters · filed 2014-03-31 | $149.47K derived: sum of 3 quarters · filed 2014-03-31 | -$80.69K 10-K · filed 2014-03-31 | $1.86M 10-K · filed 2013-04-01 | |
| 2012-09-30 | -$100.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-18 | -$53.82K derived: sum of 2 quarters · filed 2013-11-18 | -$283.98K 10-Q · filed 2013-11-18 | -$273.80K 10-Q · filed 2012-11-14 | $54.85K derived: sum of 4 quarters · filed 2013-11-18 | |
| 2012-06-30 | $46.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-15 | -$183.29K 10-Q · filed 2013-08-15 | $155.54K derived: sum of 3 quarters · filed 2013-08-15 | $696.62K derived: sum of 4 quarters · filed 2013-08-15 | ||
| 2012-03-31 | -$230.16K 10-Q · filed 2013-05-10 | $108.67K derived: sum of 2 quarters · filed 2013-05-10 | $649.75K derived: sum of 3 quarters · filed 2013-05-10 | $680.64K derived: sum of 4 quarters · filed 2013-05-10 | ||
| 2011-12-31 | $338.83K derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-01 | $879.91K derived: sum of 2 quarters · filed 2013-04-01 | $910.80K derived: sum of 3 quarters · filed 2013-04-01 | $1.05M 10-K · filed 2013-04-01 | ||
| 2011-09-30 | $541.08K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | $571.97K derived: sum of 2 quarters · filed 2012-11-14 | $709.05K 10-Q · filed 2012-11-14 | -$35.82K derived: sum of 4 quarters · filed 2012-11-14 | ||
| 2011-06-30 | $30.89K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2012-09-28 | $167.97K 10-Q/A · filed 2012-09-28 | -$576.90K derived: sum of 3 quarters · filed 2012-10-02 | -$51.14K derived: sum of 4 quarters · filed 2012-10-02 | ||
| 2011-03-31 | $137.08K 10-Q/A · filed 2012-10-02 | -$607.79K derived: sum of 2 quarters · filed 2012-10-02 | -$82.03K derived: sum of 3 quarters · filed 2012-10-02 | |||
| 2010-12-31 | -$744.87K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | -$219.11K derived: sum of 2 quarters · filed 2012-04-16 | -$49.37K 10-K · filed 2012-04-16 | |||
| 2010-09-30 | $525.76K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-21 | $695.50K 10-Q · filed 2011-11-21 | ||||
| 2010-06-30 | $169.75K 10-Q/A · filed 2011-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |